Examining the Impact of Eliminating the X Waiver on Buprenorphine Dispensation in 63 Counties in Pennsylvania.

Background: Opioid overdose rates continue to rise in the United States while access to treatment options remains limited. The X waiver, which allowed clinicians to prescribe buprenorphine, a medication for opioid use disorder (MOUD), in an outpatient setting, was eliminated in December 2022 with hopes of increasing buprenorphine access. We used a quasi-experimental approach to evaluate how eliminating the X waiver affected buprenorphine prescribing in Pennsylvania.

Global Collaboration Around Digital Mental Health: The LAMP Consortium.

Despite the great potential, there has been a lack of progress in the development of sharable and scalable tools for digital mental health due to difficulty in reproducibility and clinical application. The LAMP Platform was developed to address this gap by creating a single platform that works for a variety of clinical and research use cases. The study aims to understand how a consortium of clinical and research sites can help onboard, execute, and expand digital health research, software, and use cases.

Assessing mental health apps marketplaces with objective metrics from 29,190 data points from 278 apps.

Objective: Utilizing a standard framework that may help clinicians and patients to identify relevant mental health apps, we sought to gain a comprehensive picture of the space by searching for, downloading, and reviewing 278 mental health apps from both the iOS and Android stores.

Methods: 278 mental health apps from the Apple iOS store and Google Play store were downloaded and reviewed in a standardized manner by trained app raters using a validated framework. Apps were evaluated with this framework comprising 105 questions and covering app origin and accessibility, privacy and security, inputs and outputs, clinical foundation, features and engagement style, and interoperability.